Year: 2026
Type: article
Abstract: Acoltremon (TRYPTYR®), a first-in-class, transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist formulated as a topical 0.003% ophthalmic solution, is approved in the USA for the treatment of dry eye disease (DED) and represents a promising new treatment option. Acoltremon 0.003% demonstrated statistically significant improvements in tear production in two pivotal phase 3 trials, as well as statistically significant improvements in patient-reported signs and symptoms of DED compared with vehicle in one of these trials. Acoltremon 0.003% displayed a rapid onset of activity, with improvements in tear production evident from day 1 and sustained throughout the duration of all trials. Acoltremon 0.003% was well tolerated, including over the longer term, with low rates of study discontinuation and an overall favorable safety profile. Dry eye disease (DED) is a common condition that causes eye discomfort and adversely affects patient quality of life. Acoltremon 0.003% ophthalmic solution (TRYPTYR®) has been developed as eye drops for the treatment of the signs and symptoms of DED. When administered twice daily, acoltremon 0.003% improved DED signs and symptoms by significantly increasing tear production in two pivotal clinical trials, with significant reductions in eye discomfort also seen in one of these trials. Acoltremon 0.003% is well tolerated, with the most common adverse event being stinging or burning pain during administration, affecting 50% of trial participants; this is generally temporary and of mild severity. Therefore, acoltremon 0.003% represents a promising new treatment option for DED.
Source: Drugs & Therapy Perspectives
Authors: Kimberley Chen, Hannah A. Blair
Institution: Springer Nature (New Zealand)
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
Funder: Universität Leipzig
OpenAlex ID: W7150869254